Structural Insights into the pharmacophore of vinca domain inhibitors of microtubules

Molecular Pharmacology

Volumn 89, Issue 2, 2016, Pages 233-242

  Wang, Yuxi ^a   Benz, Frederick W ^b   Wu, Yangping ^a   Wang, Qisheng ^c   Chen, Yunfeng ^a   Chen, Xiangzheng ^a   Li, Huiyan ^a   Zhang, Yonghui ^d   Zhang, Rundong ^a   Yang, Jinliang ^a  

^a SICHUAN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BINDING; TUBULIN MODULATOR;

ANIMAL; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; MICROTUBULE; PHYSIOLOGY; PIG; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY DIFFRACTION;

ANIMALS; MICROTUBULES; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SWINE; TUBULIN MODULATORS; X-RAY DIFFRACTION;

EID: 84958173379     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.100149     Document Type: Article

References (27)

1. Akhmanova A and Steinmetz MO (2008) Tracking the ends: A dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 9:309-322.
2. Carlson K and Ocean AJ (2011) Peripheral neuropathy with microtubule-Targeting agents: occurrence and management approach. Clin Breast Cancer 11:73-81.
3. Charbaut E, Curmi PA, Ozon S, Lachkar S, Redeker V, and Sobel A (2001) Stathmin family proteins display specific molecular and tubulin binding properties. J Biol Chem 276:16146-16154.
4. Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, and Zanda M et al.. (2014) Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res 74:5700-5710.
5. Cormier A, Marchand M, Ravelli RB, Knossow M, and Gigant B (2008) Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep 9:1101-1106.
6. Cragg GM and Newman DJ (2004) A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 67: 232-244.
7. Dorléans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, and Knossow M (2009) Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci USA 106:13775-13779.
8. Dumontet C and Jordan MA (2010) Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803.
9. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
10. Etienne-Manneville S (2010) From signaling pathways to microtubule dynamics: The key players. Curr Opin Cell Biol 22:104-111.
11. Etienne-Manneville S and Hall A (2002) Rho GTPases in cell biology. Nature 420: 629-635.
12. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, and Knossow M (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435:519-522.
13. Hartley RM, Peng J, Fest GA, Dakshanamurthy S, Frantz DE, Brown ML, and Mooberry SL (2012) Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site. Mol Pharmacol 81: 431-439.
14. Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, and Tagawa ST (2014) Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther 7:2227-2236.
15. Komlodi-Pasztor E, Sackett DL, and Fojo AT (2012) Inhibitors targeting mitosis: Tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18:51-63.
16. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, and Peereboom DM et al.. (2007) Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 25: 2295-2305.
17. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Macromol Crystallogr A 276:307-326.
18. Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, and Fojo T (2004) Tumor cells resistant to a microtubuledepolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha-or betatubulin and increased microtubule stability. Biochemistry 43:13944-13954.
19. Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, Miller JH, Díaz JF, and Steinmetz MO (2014) Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl 53:1621-1625.
20. Prota AE, Bargsten K, Zurwerra D, Field JJ, Díaz JF, Altmann KH, and Steinmetz MO (2013a) Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 339:587-590.
21. Prota AE, Magiera MM, Kuijpers M, Bargsten K, Frey D, Wieser M, Jaussi R, Hoogenraad CC, Kammerer RA, and Janke Cet al.. (2013b) Structural basis of tubulin tyrosination by tubulin tyrosine ligase. J Cell Biol 200:259-270.
22. Ranaivoson FM, Gigant B, Berritt S, Joullié M, and Knossow M (2012) Structural plasticity of tubulin assembly probed by vinca-domain ligands. Acta Crystallogr D Biol Crystallogr 68:927-934.
23. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, and Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202.
24. Risinger AL, Giles FJ, and Mooberry SL (2009) Microtubule dynamics as a target in oncology. Cancer Treat Rev 35:255-261.
25. Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, and Azodi Met al.. (2013) Tubulin-b-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 119: 2582-2592.
26. Vagin AA, Steiner RA, Lebedev AA, Potterton L, McNicholas S, Long F, and Murshudov GN (2004) REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr 60: 2184-2195.
27. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, and McCoy Aet al.. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242.